PASW vs TSLA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
PASW presents a classic 'value trap' scenario, characterized by a stable Piotroski F-Score of 5/9 but catastrophic operational decay. While the balance sheet remains relatively clean with low debt and a healthy current ratio, the company has suffered a massive 62% year-over-year revenue collapse and negative profit margins. The 95% decline in share price over the last year reflects a fundamental breakdown in the business model, which is not offset by the low Price-to-Book ratio of 0.51.
Tesla's deterministic health is stable with a Piotroski F-Score of 4/9, but its valuation is fundamentally disconnected from current performance. The Graham Number ($22.85) and Intrinsic Value ($7.42) indicate extreme overvaluation relative to the current price of $343.25. With negative YoY revenue growth (-3.10%) and a collapse in earnings growth (-60.60%), the P/E ratio of 323.82 is unsustainable. Technical trends and insider activity are both strongly bearish, suggesting a significant correction is likely.
Compare Another Pair
Related Comparisons
PASW vs TSLA: Head-to-Head Comparison
This page compares Ping An Biomedical Co., Ltd. (PASW) and Tesla, Inc. (TSLA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.